Table 1. Summary of Phase II studies. Determination of dosage and clinical outcome. † Clinical cure is resolution of diarrhea following the recommended dose of drug (fidaxomicin: 200 mg twice a day; ...

Clostridium difficile infection (CDI) is a common hospital-acquired infection that is associated with a high clinical and economic burden. Because of this management of CDI is quickly becoming a part ...

Clinical cure and no disease recurrence within 60 days without additional treatment was observed in 66.7% of 51 patients receiving FMT vs 61.2% of 49 patients receiving vancomycin. HealthDay News — ...

Clostridium bacteria, computer illustration. Clostridia are spore-forming bacteria that include several human pathogenic species, C. difficile, C. tetani, C. botulinum, C. perfringens, and others. C.

Active ingredient: Fidaxomicin 200 mg; tablets. Indication: For the treatment of Clostridium difficile-associated diarrhea (CDAD). Pharmacology: Fidaxomicin is a fermentation product from the ...

Please provide your email address to receive an email when new articles are posted on . FMT appeared as effective as vancomycin in curing first-time C. difficile infection. Findings show FMT has ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Oral vancomycin safely induced and maintained remission of ulcerative colitis among a subset of ...

Vancomycin 265/309 (85.8%) 76/265 (25.3%) 198/309 (64.1%) † Clinical cure is resolution of diarrhea following the recommended dose of drug (fidaxomicin: 200 mg twice a day; vancomycin: 125 mg four ...

Clinical cure and no disease recurrence within 60 days for 66.7 percent in FMT group, 61.2 percent in vancomycin group. (HealthDay News) — Fecal microbiota transplantation (FMT) could be considered as ...